Neurocrine names Eiry W. Roberts CMO and Neurocrine Biosciences stock gains 1.74 percent

Published on 10/02/2026 at 21:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter 2026 revenue reached USD 959.0 million. Neurocrine Biosciences stock costs EUR 127.33 on October 2, 2026 after EUR 125.15.

NBIX, US64125C1099, Illustration mit AI erstellt.

Neurocrine Biosciences (ISIN US64125C1099) was trading at EUR 127.33 at Lang & Schwarz on October 2, 2026 at 9:47 p.m. CEST, plus 1.74 percent versus the prior close of EUR 125.15. On September 28, 2026, Neurocrine appointed Eiry W. Roberts, M.D., as chief medical officer, succeeding Sanjay Keswani, M.D., by mutual agreement, according to Trivano.

Leadership returns to late-stage programs

Roberts previously served as Neurocrine's chief medical officer from 2018 to 2025 and later became a strategic advisor. The September 28, 2026 release says her return is intended to support indication expansion for INGREZZA and development of the crinecerfont program, which led to approval of CRENESSITY.

The leadership change comes as the company advances several clinical programs and prepares for additional milestones. That makes the medical role relevant beyond personnel: execution across the pipeline is now a measurable operating priority.

Revenue growth raises the bar

For the second quarter of 2026, Neurocrine reported USD 959.0 million of revenue, a 39.00 percent increase from the same quarter of 2025, according to StockTitan. GAAP net income was USD 144.0 million, or USD 1.39 in diluted earnings per share, while non-GAAP net income reached USD 297.0 million, or USD 2.85 in non-GAAP earnings per share.

The same filing summary states that INGREZZA generated USD 716.0 million in second-quarter 2026 net product sales, while CRENESSITY contributed USD 184.0 million and VYKAT XR contributed USD 54.0 million. Neurocrine also raised 2026 INGREZZA net sales guidance to USD 2.825 billion to USD 2.875 billion, giving investors a clearer test for commercial execution.

Analyst target moves lower

On September 29, 2026, UBS lowered its Neurocrine price target from USD 231.00 to USD 214.00 and retained a Buy rating, as MarketBeat reported. The cut contrasts with the latest operating figures: revenue growth reached 39.00 percent, while GAAP net income was USD 144.0 million for the second quarter.

Neurocrine's next earnings date is October 28, 2026, according to Yahoo Finance. The upcoming report will put the new medical leadership, the VYKAT XR launch contribution and the raised INGREZZA outlook against another set of reported results.

NBIX gains in after-hours trading

NBIX was trading at EUR 127.33 at Lang & Schwarz on October 2, 2026 at 9:47 p.m. CEST, plus 1.74 percent versus the Lang & Schwarz prior close of EUR 125.15 on October 1, 2026. The reference price is in after-hours trading, while the primary listing is on Nasdaq.